Synergen, Inc.

ANTRIL

pharmaceuticals; namely, drugs for use in the treatment of arthritis, cardiovascular injury and bowel disease;

ANTRIL

pharmaceuticals, including protein-based and other pharmaceuticals for use in treating diseases, including inflammatory diseases, chronic skin ulcers, neurological disorders, rheumatoid arthritis, sepsis and septic shock, leukemia, cystic fibrosis, genetic emphysema and peripheral neuropathies, sepsis syndrome; systemic inflammatory response syndrome ( SIRS) due to sepsis; pancreatitis; burns and cachexia; asthma; inflammatory bowel disease; graft versus host disease; and stroke; IL-1 mediated diseases;

S

The mark consists of the letter S and design.;Research and Development Services for Others in the Fields of Molecular Biology, Biochemistry and Genetic Engineering;